Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 304

1.

IRF9 and unphosphorylated STAT2 cooperate with NF-κB to drive IL6 expression.

Nan J, Wang Y, Yang J, Stark GR.

Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3906-3911. doi: 10.1073/pnas.1714102115. Epub 2018 Mar 26.

2.

The FACT inhibitor CBL0137 synergizes with cisplatin in small cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells.

De S, Lindner DJ, Coleman C, Wildey G, Dowlati A, Stark GR.

Cancer Res. 2018 Feb 13. pii: canres.1920.2017. doi: 10.1158/0008-5472.CAN-17-1920. [Epub ahead of print]

PMID:
29440145
3.

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.

Doherty MR, Cheon H, Junk DJ, Vinayak S, Varadan V, Telli ML, Ford JM, Stark GR, Jackson MW.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13792-13797. doi: 10.1073/pnas.1713728114. Epub 2017 Dec 11.

4.

CDK8/19 Mediator kinases potentiate induction of transcription by NFκB.

Chen M, Liang J, Ji H, Yang Z, Altilia S, Hu B, Schronce A, McDermott MSJ, Schools GP, Lim CU, Oliver D, Shtutman MS, Lu T, Stark GR, Porter DC, Broude EV, Roninson IB.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10208-10213. doi: 10.1073/pnas.1710467114. Epub 2017 Aug 30.

5.

Responses to Cytokines and Interferons that Depend upon JAKs and STATs.

Stark GR, Cheon H, Wang Y.

Cold Spring Harb Perspect Biol. 2018 Jan 2;10(1). pii: a028555. doi: 10.1101/cshperspect.a028555. Review.

PMID:
28620095
6.

Hypoxia sensing through β-adrenergic receptors.

Cheong HI, Asosingh K, Stephens OR, Queisser KA, Xu W, Willard B, Hu B, Dermawan JK, Stark GR, Naga Prasad SV, Erzurum SC.

JCI Insight. 2016 Dec 22;1(21):e90240. doi: 10.1172/jci.insight.90240.

7.

Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387.

Wang Y, Nan J, Willard B, Wang X, Yang J, Stark GR.

EMBO J. 2017 Jan 17;36(2):202-212. doi: 10.15252/embj.201694834. Epub 2016 Nov 16.

8.

Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.

Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, Stark GR, Venere M.

Cancer Res. 2016 Apr 15;76(8):2432-42. doi: 10.1158/0008-5472.CAN-15-2162. Epub 2016 Feb 26.

9.

Response to interferons and antibacterial innate immunity in the absence of tyrosine-phosphorylated STAT1.

Majoros A, Platanitis E, Szappanos D, Cheon H, Vogl C, Shukla P, Stark GR, Sexl V, Schreiber R, Schindler C, Müller M, Decker T.

EMBO Rep. 2016 Mar;17(3):367-82. doi: 10.15252/embr.201540726. Epub 2016 Feb 12.

10.

A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis.

Wu L, Chen X, Zhao J, Martin B, Zepp JA, Ko JS, Gu C, Cai G, Ouyang W, Sen G, Stark GR, Su B, Vines CM, Tournier C, Hamilton TA, Vidimos A, Gastman B, Liu C, Li X.

J Exp Med. 2015 Sep 21;212(10):1571-87. doi: 10.1084/jem.20150204. Epub 2015 Sep 7.

11.

NF-κB: Regulation by Methylation.

Lu T, Stark GR.

Cancer Res. 2015 Sep 15;75(18):3692-5. doi: 10.1158/0008-5472.CAN-15-1022. Epub 2015 Sep 3. Review.

12.

Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness.

Sung PS, Cheon H, Cho CH, Hong SH, Park DY, Seo HI, Park SH, Yoon SK, Stark GR, Shin EC.

Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10443-8. doi: 10.1073/pnas.1513341112. Epub 2015 Jul 27.

13.

Erlotinib protects against LPS-induced endotoxicity because TLR4 needs EGFR to signal.

De S, Zhou H, DeSantis D, Croniger CM, Li X, Stark GR.

Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9680-5. doi: 10.1073/pnas.1511794112. Epub 2015 Jul 20.

14.

Cooperative Transcriptional Activation of Antimicrobial Genes by STAT and NF-κB Pathways by Concerted Recruitment of the Mediator Complex.

Wienerroither S, Shukla P, Farlik M, Majoros A, Stych B, Vogl C, Cheon H, Stark GR, Strobl B, Müller M, Decker T.

Cell Rep. 2015 Jul 14;12(2):300-12. doi: 10.1016/j.celrep.2015.06.021. Epub 2015 Jul 2.

15.

STAT3-driven transcription depends upon the dimethylation of K49 by EZH2.

Dasgupta M, Dermawan JK, Willard B, Stark GR.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):3985-90. doi: 10.1073/pnas.1503152112. Epub 2015 Mar 12.

16.

Using sequential immunoprecipitation and mass spectrometry to identify methylation of NF-κB.

Lu T, Stark GR.

Methods Mol Biol. 2015;1280:383-93. doi: 10.1007/978-1-4939-2422-6_23.

PMID:
25736762
17.

Critical role for lysine 685 in gene expression mediated by transcription factor unphosphorylated STAT3.

Dasgupta M, Unal H, Willard B, Yang J, Karnik SS, Stark GR.

J Biol Chem. 2014 Oct 31;289(44):30763-71. doi: 10.1074/jbc.M114.603894. Epub 2014 Sep 12.

18.

Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs.

Kolosenko I, Fryknäs M, Forsberg S, Johnsson P, Cheon H, Holvey-Bates EG, Edsbäcker E, Pellegrini P, Rassoolzadeh H, Brnjic S, Larsson R, Stark GR, Grandér D, Linder S, Tamm KP, De Milito A.

Int J Cancer. 2015 Feb 15;136(4):E51-61. doi: 10.1002/ijc.29161. Epub 2014 Sep 4.

19.

EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells.

De S, Dermawan JK, Stark GR.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11721-6. doi: 10.1073/pnas.1412390111. Epub 2014 Jul 28.

20.

Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.

Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, Sharma N, Stark GR.

Mol Cancer Ther. 2014 Sep;13(9):2203-14. doi: 10.1158/1535-7163.MCT-14-0013. Epub 2014 Jul 15.

21.

Interferons and their stimulated genes in the tumor microenvironment.

Cheon H, Borden EC, Stark GR.

Semin Oncol. 2014 Apr;41(2):156-73. doi: 10.1053/j.seminoncol.2014.02.002. Epub 2014 Feb 14. Review.

22.

Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism.

Qiu J, Thapaliya S, Runkana A, Yang Y, Tsien C, Mohan ML, Narayanan A, Eghtesad B, Mozdziak PE, McDonald C, Stark GR, Welle S, Naga Prasad SV, Dasarathy S.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18162-7. doi: 10.1073/pnas.1317049110. Epub 2013 Oct 21.

23.

STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor.

Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J, Stark GR.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16975-80. doi: 10.1073/pnas.1315862110. Epub 2013 Sep 30.

24.

IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage.

Cheon H, Holvey-Bates EG, Schoggins JW, Forster S, Hertzog P, Imanaka N, Rice CM, Jackson MW, Junk DJ, Stark GR.

EMBO J. 2013 Oct 16;32(20):2751-63. doi: 10.1038/emboj.2013.203. Epub 2013 Sep 24.

25.

Role of lysine methylation of NF-κB in differential gene regulation.

Lu T, Yang M, Huang DB, Wei H, Ozer GH, Ghosh G, Stark GR.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13510-5. doi: 10.1073/pnas.1311770110. Epub 2013 Jul 31.

26.

PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB.

Wei H, Wang B, Miyagi M, She Y, Gopalan B, Huang DB, Ghosh G, Stark GR, Lu T.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13516-21. doi: 10.1073/pnas.1311784110. Epub 2013 Jul 31.

27.

PHF20 regulates NF-κB signalling by disrupting recruitment of PP2A to p65.

Zhang T, Park KA, Li Y, Byun HS, Jeon J, Lee Y, Hong JH, Kim JM, Huang SM, Choi SW, Kim SH, Sohn KC, Ro H, Lee JH, Lu T, Stark GR, Shen HM, Liu ZG, Park J, Hur GM.

Nat Commun. 2013;4:2062. doi: 10.1038/ncomms3062.

28.

FAM83B mediates EGFR- and RAS-driven oncogenic transformation.

Cipriano R, Graham J, Miskimen KL, Bryson BL, Bruntz RC, Scott SA, Brown HA, Stark GR, Jackson MW.

J Clin Invest. 2012 Sep;122(9):3197-210. doi: 10.1172/JCI60517. Epub 2012 Aug 13.

29.

The JAK-STAT pathway at twenty.

Stark GR, Darnell JE Jr.

Immunity. 2012 Apr 20;36(4):503-14. doi: 10.1016/j.immuni.2012.03.013. Review.

30.

The role of cell type-specific responses in IFN-β therapy of multiple sclerosis.

Zula JA, Green HC, Ransohoff RM, Rudick RA, Stark GR, van Boxel-Dezaire AH.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19689-94. doi: 10.1073/pnas.1117347108. Epub 2011 Nov 21.

31.

Pillars article: A protein tyrosine kinase in the interferon α/β signaling pathway. Cell. 1992. 70: 313-322.

Velazquez L, Fellous M, Stark GR, Pellegrini S.

J Immunol. 2011 Dec 1;187(11):5479-88. No abstract available.

32.

Caspase-8-mediated cleavage inhibits IRF-3 protein by facilitating its proteasome-mediated degradation.

Sears N, Sen GC, Stark GR, Chattopadhyay S.

J Biol Chem. 2011 Sep 23;286(38):33037-44. doi: 10.1074/jbc.M111.257022. Epub 2011 Aug 4.

33.

FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaB.

Guo C, Stark GR.

Proc Natl Acad Sci U S A. 2011 May 10;108(19):7968-73. doi: 10.1073/pnas.1105369108. Epub 2011 Apr 25.

34.

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, MacSwords J, Eyler CE, McLendon RE, Heddleston JM, Shou W, Hambardzumyan D, Lee J, Hjelmeland AB, Sloan AE, Bredel M, Stark GR, Rich JN, Bao S.

Cancer Cell. 2011 Apr 12;19(4):498-511. doi: 10.1016/j.ccr.2011.03.004.

35.

Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.

Tan MH, De S, Bebek G, Orloff MS, Wesolowski R, Downs-Kelly E, Budd GT, Stark GR, Eng C.

Breast Cancer Res Treat. 2012 Feb;131(3):849-58. doi: 10.1007/s10549-011-1500-8. Epub 2011 Apr 9.

36.

The dual functions of IL-1 receptor-associated kinase 2 in TLR9-mediated IFN and proinflammatory cytokine production.

Wan Y, Kim TW, Yu M, Zhou H, Yamashita M, Kang Z, Yin W, Wang JA, Thomas J, Sen GC, Stark GR, Li X.

J Immunol. 2011 Mar 1;186(5):3006-14. doi: 10.4049/jimmunol.1003217. Epub 2011 Jan 26.

37.

The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins.

Cheon H, Yang J, Stark GR.

J Interferon Cytokine Res. 2011 Jan;31(1):33-40. doi: 10.1089/jir.2010.0100. Epub 2010 Dec 19. Review.

38.

Lysine methylation of promoter-bound transcription factors and relevance to cancer.

Stark GR, Wang Y, Lu T.

Cell Res. 2011 Mar;21(3):375-80. doi: 10.1038/cr.2010.174. Epub 2010 Dec 14.

39.

Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes.

Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, Wang B, Chance MR, Chen X, Du Y, Wang Y, An L, Wang Q, Lu T, Zhang X, Wang Z, Stark GR.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21499-504. doi: 10.1073/pnas.1016147107. Epub 2010 Nov 23.

40.

Major differences in the responses of primary human leukocyte subsets to IFN-beta.

van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, Stark GR.

J Immunol. 2010 Nov 15;185(10):5888-99. doi: 10.4049/jimmunol.0902314. Epub 2010 Oct 18.

41.

Activation of cAMP-responsive-element-binding protein by PI3 kinase and p38 MAPK is essential for elevated expression of transforming growth factor β2 in cancer cells.

Wan Y, Yang M, Kolattukudy S, Stark GR, Lu T.

J Interferon Cytokine Res. 2010 Sep;30(9):677-81. doi: 10.1089/jir.2009.0117.

42.

Use of forward genetics to discover novel regulators of NF-kappaB.

Lu T, Stark GR.

Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a001966. doi: 10.1101/cshperspect.a001966. Epub 2009 Dec 23. Review.

43.

Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65.

Lu T, Jackson MW, Wang B, Yang M, Chance MR, Miyagi M, Gudkov AV, Stark GR.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):46-51. doi: 10.1073/pnas.0912493107. Epub 2009 Dec 22.

44.

Roles of IKK-beta, IRF1, and p65 in the activation of chemokine genes by interferon-gamma.

Shultz DB, Rani MR, Fuller JD, Ransohoff RM, Stark GR.

J Interferon Cytokine Res. 2009 Dec;29(12):817-24. doi: 10.1089/jir.2009.0034.

45.

Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB.

Lu T, Jackson MW, Singhi AD, Kandel ES, Yang M, Zhang Y, Gudkov AV, Stark GR.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16339-44. doi: 10.1073/pnas.0908560106. Epub 2009 Sep 1.

46.

Overexpression of kinesins mediates docetaxel resistance in breast cancer cells.

De S, Cipriano R, Jackson MW, Stark GR.

Cancer Res. 2009 Oct 15;69(20):8035-42. doi: 10.1158/0008-5472.CAN-09-1224. Epub 2009 Sep 29.

47.

Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes.

Cheon H, Stark GR.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9373-8. doi: 10.1073/pnas.0903487106. Epub 2009 May 28.

48.

Interleukin-1 receptor-associated kinase 2 is critical for lipopolysaccharide-mediated post-transcriptional control.

Wan Y, Xiao H, Affolter J, Kim TW, Bulek K, Chaudhuri S, Carlson D, Hamilton T, Mazumder B, Stark GR, Thomas J, Li X.

J Biol Chem. 2009 Apr 17;284(16):10367-75. doi: 10.1074/jbc.M807822200. Epub 2009 Feb 18.

49.

Transposon-based mutagenesis identifies short RIP1 as an activator of NFkappaB.

Dasgupta M, Agarwal MK, Varley P, Lu T, Stark GR, Kandel ES.

Cell Cycle. 2008 Jul 15;7(14):2249-56. Epub 2008 May 17.

PMID:
18635966
50.

DNA synthesis from unbalanced nucleotide pools causes limited DNA damage that triggers ATR-CHK1-dependent p53 activation.

Hastak K, Paul RK, Agarwal MK, Thakur VS, Amin AR, Agrawal S, Sramkoski RM, Jacobberger JW, Jackson MW, Stark GR, Agarwal ML.

Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6314-9. doi: 10.1073/pnas.0802080105. Epub 2008 Apr 23.

Supplemental Content

Loading ...
Support Center